Pyxis Oncology, Inc. — Investor Relations & Filings

Pyxis Oncology, Inc. is a clinical-stage company focused on developing next-generation therapeutics for difficult-to-treat cancers. The company's differentiated portfolio of clinical assets is centered on two primary modalities: antibody-drug conjugates (ADCs) and immuno-oncology (IO). Its ADC technology platform is designed to deliver potent cancer-killing agents directly to tumor cells for enhanced safety and efficacy. The immuno-oncology programs utilize monoclonal antibodies (mAbs) to mobilize the body's immune system to attack cancer cells by blocking tumor defense mechanisms and overcoming immune suppression. Pyxis Oncology is advancing its product candidates as both monotherapies and in combination with other therapies to improve outcomes for patients with solid tumors.